ArticleJournal for immunotherapy of cancer2022

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.

Robert I Haddad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.